Tetrahydrocannabinol (THC) Cannabinoid Research

Tetrahydrocannabinol (THC) Research Dashboard


Primary Studies


Related Studies


Total Studies

Clinical Studies


Clinical Meta-analyses


Double-blind human trials


Clinical human trials

Pre-Clinical Studies




Animal studies


Laboratory studies

What am I missing as a non-subscriber?

To see a full dashboard with study details and filtering, go to our DEMO page.

As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.

CannaKeys has 1153 studies associated with Tetrahydrocannabinol (THC).

Here is a small sampling of Tetrahydrocannabinol (THC) studies by title:

Components of the Tetrahydrocannabinol (THC) Research Dashboard

  • Top medical conditions associated with Tetrahydrocannabinol (THC)
  • Proven effects in clinical trials for Tetrahydrocannabinol (THC)
  • Receptors associated with Tetrahydrocannabinol (THC)
  • Individual study details for Tetrahydrocannabinol (THC)

Ready to become a subscriber? Go to our PRICING page.

Select New Cannabinoid

Filter Cannabinoid

Members can filter by the following criteria:

  • Study Type
  • Organ Systems
  • Terpenes
  • Receptors
  • Ligands
  • Study Result
  • Year of Publication

Overview - Tetrahydrocannabinol (THC)

Description of Tetrahydrocannabinol (THC)

The plant-based (phytocannabinoid) delta-9-tetrahydrocannabinol (THC) was discovered in 1964 and by 2016 thirty-one distinct members had been identified. THC is primarily (but not exclusively) responsible for many of therapeutic and adverse mind-altering effects associated with the herb. THC is the most studied of all cannabis' individual parts. THC is exclusive to cannabis, but it is also produced synthetically.

Other Names:

Delta 9-Tetrahydrocannabinol
Dronabinol, Marinol, Delta9-THC

IUPAC Name: (6aR,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol

Molecular Formula: C21H30O2


Tetrahydrocannabinol (THC) Properties and Effects

THC is a multi-target molecule. THC-abundant cannabis plants or products (i.e., chemotype I) have proven effects such as bronchodilation (CB1 inhibits cholinergic contraction of bronchi), appetite stimulation, down-regulation of the body’s own immune responses, and potent analgesic properties in cases of central pains. As such they have been employed therapeutically in patients with asthma, HIV/AIDS-related anorexia, rheumatoid arthritis, or spinal cord injuries.

The multiple and simultaneous effects of THC when understood and used with its complexity in mind can produce a great number of safe and therapeutic results. However, cannabis (especially THC-abundant types) can make things worse especially in THC-sensitive individuals or in a number of very specific cases.

For instance, while THC has been shown to work via a number of pathways by which it can create apoptotic (anti-cancer) effects, various pre-clinical trials have discovered that colon, ovarian, and metastasizing breast cancer cell lines rely, at least in part, on GPR-55 for proliferation. Since THC is an agonist at GPR-55 and CBD an antagonist at the same receptor, these early study results suggest caution in using a THC-rich type of cannabis for these particular cancers. While it might turn out that THC’s positive effects via CB1 or CB2 outweigh the potential pitfalls of GPR-55 activation on possible proliferation, a THC/CBD balanced type of cannabis or cannabis-based therapeutic may be the advisable option until the science becomes more discerning for this specific situations.

Other examples of using caution when using a type of cannabis containing mostly THC include patients with pancreatitis, individuals with vulnerabilities to developing psychosis, adolescents, or during pregnancy, all of which especially warrant caution and careful discernment.

Tetrahydrocannabinol (THC) Receptor Binding

Endocannabinoid System
• CB1 moderate affinity for (Mean Ki 25nM)
• CB2 moderate affinity for (Mean Ki 35nM)

Endocannabinoidome (eCBome)
• GPR18 (agonist)
• GPR55 (agonist) the reader is reminded that CBD is an antagonist at the same receptor site
• Adenosine 1 (A1 inhibitor)
• Negative allosteric modulator at 5-HT1A (diminishes action of an agonist)
• PPAR γ (agonist)
• Delta Opioid Receptors [DOR (δ-Delta)]
• Mu Opioid Receptors [MOR (μ-Mu)]
• TRPV2 (agonist)
• TRPV3 (antagonist)
• TRPM8 (antagonist)
In addition, THC modulates various neurotransmitter activation via (+ or -) allosteric mechanisms (e.g. glutamate, epinephrine, adenosine)

Disclaimers: Information on this site is provided for informational purposes only and is not meant to substitute for the advice provided by your own physician or other medical professional. You should not use the information contained herein for diagnosing a health problem or disease. If using a product, you should read carefully all product packaging. If you have or suspect that you have a medical problem, promptly contact your health care provider.

Information on this site is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your physician, nutritionally oriented health care practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications.